Rituximab is a medication commonly used to treat B-cell cancers such as non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). However, the cancer often comes back. In this study, researchers want to find the highest dose of an investigational drug called urelumab (BMS-663513) that can be given safely with rituximab in patients with B-cell NHL or CLL.
Urelumab is an antibody which recognizes a protein on immune cells called CD137. By binding to CD137, urelumab may stimulate patients’ immune cells to attack their cancer cells. The action of urelumab can help overcome resistance that patients’ cancer cells may have developed to rituximab. Both drugs are given intravenously (by vein).